Tesamorelin Research Overview (also known as Egrifta)
A synthetic stabilized analog of GHRH studied for its targeted effects on visceral fat reduction, metabolic health improvement, sleep quality, and GH/IGF-1 output. The only GHRH analog with FDA approval, for HIV-associated lipodystrophy under the brand name Egrifta.
"What Is Tesamorelin?
Tesamorelin (Egrifta) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) conjugated to a trans-3-hexenoic acid group at its N-terminus — protecting it from enzymatic degradation and extending its half-life while maintaining GHRH receptor binding potency. It is FDA-approved for the treatment of excess abdominal (visceral) fat in HIV-infected patients with lipodystrophy — the only GHRH analog with regulatory approval for a metabolic indication.
Mechanism of Action
Tesamorelin activates GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and secretion. The resulting GH pulses increase IGF-1 and promote lipolysis preferentially from visceral adipose tissue, which is more metabolically active and GH-responsive than subcutaneous fat. This preferential visceral fat mobilization is the primary mechanism driving the reductions documented in clinical trials.
Clinical Evidence and Cognitive Research
AWARE trials demonstrated 15–20% reductions in visceral adipose tissue area by CT over 26 weeks, significant improvements in lipid parameters, and improved body image in HIV patients with lipodystrophy. Emerging research has examined Tesamorelin's effects on cognitive function in older adults and HIV patients, with findings suggesting improvements in executive function and memory accompanying GH/IGF-1 restoration.
Quick Reference
| Literature-Reported Dose Range | 0.5–2.0 mg daily |
| Literature-Reported Frequency | Once daily |
| Literature-Reported Cycle Length | 12–26 weeks |
| Literature-Reported Washout | 4–6 weeks |
| Storage | Unreconstituted powder: refrigerate at 2-8°C. Reconstituted solution: room temperature (20-25°C) — do NOT refrigerate after mixing. Use SV immediately, WR stable 7 days. |
| Sites Reported in Studies | SubQ: Abdomen (avoid navel ±2 inches), rotate sites, avoid bruises/scars |
| Timing | Empty AM or PM fasted, bedtime dose optimal for sleep-phase GH pulse |
Research Indications
Weight Loss
HIV-Associated Lipodystrophy
FDA-approved indication showing 15-20% visceral fat reduction in clinical trials
Selective Visceral Fat Targeting
Unique mechanism spares subcutaneous fat while reducing harmful visceral adiposity
Sustained Fat Loss
Maintained weight loss with continuous treatment over 52+ weeks in clinical studies
Metabolic
Triglyceride Reduction
12.3% triglyceride reduction demonstrated in pooled analysis of clinical trials
Cholesterol Profile Improvement
7.2% improvement in cholesterol/HDL ratio with daily 2mg dosing
NAFLD Treatment
37% liver fat reduction over 12 months in HIV patients with fatty liver disease
Muscle Growth
Lean Muscle Mass Preservation
Maintains muscle mass during fat loss, unlike conventional weight loss methods
Muscle Density Enhancement
Improved muscle composition and density through IGF-1 mediated mechanisms
IGF-1 Elevation
26% increase in IGF-1 levels supporting muscle growth and recovery processes
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| HIV Lipodystrophy (FDA Approved) | 1.4 mg daily | Once daily | SubQ (abdomen) |
| Visceral Fat Reduction | 2 mg daily | Once daily | SubQ (rotate sites) |
| Anti-aging/Body Composition | 1-2 mg daily | 5-7 days/week | SubQ (evening) |
| NAFLD Treatment | 2 mg daily | Once daily | SubQ for 12 months |
| Cognitive Enhancement | 1 mg daily | Once daily | SubQ for 20 weeks |
| Research Protocol | 1-2 mg daily | Daily | SubQ with cycle breaks |
Timing
Recommended administration window: evening injection preferred for natural GH rhythm support. Typical onset: iGF-1 elevation: 13 days; Visible fat loss: 4-8 weeks; Peak effects: 12-26 weeks.
Peptide Interactions
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
Synergistic GH stimulation IGF-1 levels closely and consider dose adjustments to prevent excessive growth hormone elevation.
Both are GHRH analogs. Combining creates GHRH receptor competition and redundancy — no additive benefit, potential desensitization. Choose one GHRH analog per protocol.
Both target GHRH receptors but with conflicting release patterns. Tesamorelin promotes pulsatile GH release while DAC provides continuous stimulation, disrupting natural GH rhythms and accelerating receptor downregulation.
Both are GHRH analogs — combining them is redundant and counterproductive. Tesamorelin is the most potent; Sermorelin is the most physiological. Use one.
Tesamorelin increases diabetes risk (3.3-fold). Monitor blood glucose closely and adjust insulin doses as needed during treatment.
No direct interactions reported. May help mitigate glucose intolerance risk associated with Tesamorelin therapy.
Decreases corticosteroid effectiveness. Consider increasing steroid doses or using alternative anti-inflammatory therapy.
Somatostatin analog directly blocks GH release, completely negating Tesamorelin's therapeutic effects.
Redundant and potentially dangerous combination. Risk of acromegaly and metabolic complications from excessive GH exposure.
Reported Research Timeline
01Week 1–2 (reported in cited studies): iGF-1 levels begin to rise, possible mild water retention or joint discomfort
02Week 4–6 (reported in cited studies): early metabolic changes, slight improvements in energy and sleep quality
03Week 8–12 (reported in cited studies): visible visceral fat reduction begins, waist circumference may decrease
04Week 12–26 (reported in cited studies): peak effects achieved with significant body composition improvements
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Monitor blood glucose regularly - 3.3-fold increased diabetes risk documented
IGF-1 levels should be checked monthly - 47% exceed normal range at 26 weeks
Not Recommended in active malignancy or pituitary disorders
Common side effects include injection site reactions (17%) and joint pain (13%)
Seek Medical Attention If:
Development of diabetes or severe glucose intolerance (HbA1c ≥6.5%)
Signs of malignancy or suspicious growths
Severe hypersensitivity reactions or persistent injection site reactions
Excessive IGF-1 elevation (>2 SD above normal) with acromegaly symptoms
Quality Indicators
Verified Marker
FDA-approved formulations
Egrifta SV or Egrifta WR from licensed pharmacy with proper documentation
Verified Marker
White crystalline powder
Lyophilized powder should be white, uniform, and cake-like in appearance
Verified Marker
Clear reconstituted solution
After mixing, solution should be clear and colorless without particles
Verified Marker
Proper packaging integrity
Sealed vials with intact rubber stoppers and aluminum seals
Quality Concern
Discolored or cloudy solution
Any yellow/brown color or cloudiness indicates degradation or contamination
Quality Concern
Visible particles or precipitate
Particles indicate protein aggregation or bacterial contamination
Acceptable Range
Compounded formulations
Non-FDA approved compounded versions may have quality/potency variability
Research Citations
- Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz, J., Allas, S., Blot, K., et al., 2010, Journal of Clinical Endocrinology & Metabolism - Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Stanley, T.L., Fourman, L.T., Zheng, I., et al., 2019, The Lancet HIV - Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Fourman, L.T., Billingsley, J.M., Daniels, K., et al., 2021, Scientific Reports - Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction
Grinspoon, S.K., Fitch, K.V., Zanni, M.V., et al., 2013, AIDS - The effects of tesamorelin on muscle and bone parameters in HIV-infected patients with abdominal fat accumulation
Adrian, S., Scherzinger, D., Sanchez, R., et al., 2019, The Journal of Frailty & Aging - Effects of growth hormone-releasing factor on visceral fat, metabolic, and cardiovascular indices in human immunodeficiency virus-infected patients with abdominal fat accumulation
Kotler, D.P., Muurahainen, N., Grunfeld, C., et al., 2017, PLoS One - Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Falutz, J., Mamputu, J.C., Potvin, D., et al., 2006, Journal of Clinical Endocrinology & Metabolism - FDA Approval Package for Egrifta (tesamorelin) for injection
US Food and Drug Administration, 2010, FDA Drug Approval Package - Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
Baker, L.D., Barsness, S.M., Borson, S., et al., 2012, Archives of Neurology - Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging
Friedman, S.D., Baker, L.D., Borson, S., et al., 2013, JAMA Neurology - Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, 2026, Am J Sports Med - Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L, 2026, Int J Mol Sci - Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss
Arora G, Conde KR, Desouza CV, 2026, J Clin Med - Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Villegas Meza AD, Nocek M, Mitchell BC, 2026, JBJS Rev - Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation
Chisholm TS, Kulkarni SS, Hossain KR, 2020, J Am Chem Soc - FDA Drug Label: EGRIFTA SV (BLA022505)
U.S. Food & Drug Administration, FDA Drug Label
"
Research Focus
Visceral fat reduction, HIV lipodystrophy, Growth hormone release, Metabolic health, Cognitive function
Verified Vendors Carrying Tesamorelin
Frequently Asked Questions
What should researchers watch for with Tesamorelin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Tesamorelin?
Week 1–2 (reported in cited studies): iGF-1 levels begin to rise, possible mild water retention or joint discomfort
How is Tesamorelin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →